DTIL - Precision BioSciences Inc. Analyst Forecast Prices
The Precision BioSciences (DTIL) biotech environment relies on the ARCUS platform, where patent protection for DNA insertion retains B2B clients, while development depends on FDA approval. Research efficiency is guaranteed by strict control over the transport of reagents and bioreactors. Historical price action, reaching 29.37, confirms the company's potential in the gene therapy segment through precision gene editing for the creation of CAR-T cells.
Metric breakdowns and analytics for Precision BioSciences, Inc. (DTIL)
- stock price and consensus target price:
- market capitalization statistics:
- book capitalization information:
- debt obligations and liquidity statistics:
Debt to Equity Ratio Precision BioSciences|DTIL - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Precision BioSciences Inc.|DTIL - Company Aggregate Debts|Debts to Book Capitalization Precision BioSciences|DTIL - Company Long-Term Debt|Current Liabilities Precision BioSciences|Intermediate Coverage Ratio precisionbiosciences.com
- net income and valuation ratios data:
DTIL - Net Profit|Expected Net Profit Precision BioSciences|DTIL - P/E Multiple|Projected Price to Earnings precisionbiosciences.com|DTIL - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Precision BioSciences|DTIL - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Precision BioSciences|DTIL - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months precisionbiosciences.com|DTIL - Earnings per share growth in current year|Expected net earnings per share growth next year Precision BioSciences
General company analysis:DTIL precisionbiosciences.com
Finding a balance between operational risks and return on capital at Precision BioSciences requires accounting for enzyme logistics efficiency to minimize clinical cycle delays. The current consensus price target aggregates expert expectations for the fair value of DTIL, reflecting the market's absorption rate of new data, which allows investors to assess the business model's resilience to volatility amid low liquidity.
Competitors of Precision BioSciences
tempus.com - Broker Consensus Forecast|Qiagen - Consensus Target|Analyst Forecast Prices IONS (Ionis Pharmaceuticals, Inc.)|Repligen Corp. - Analyst Consensus Forecast|Analyst Median Target Avidity Corp RNA|CRISPR Therapeutics AG (CRSP) - Price Target Chart|WGS (genedx.com) - Price Target Chart|RARE (Ultragenyx) - Analyst Consensus Forecast|Broker Consensus Forecast BEAM (Beam Therapeutics Inc)|Price Target Chart Sarepta Therapeutics Inc (SRPT)|Twist Bioscience Corp - Broker Consensus Forecast|Analyst Consensus Forecast TXG (10x Genomics, Inc.)|Analyst Consensus Forecast intelliatx.com NTLA|STOK - Price Target Chart|Forecast Levels Chart BLFS|Wave Life Sciences Corp (WVE) - Price Target Chart|Maze Therapeutics Corp - Fair Value Consensus|SION (Sionna Therapeutics Inc) - Analyst Consensus Forecast|Average Forecast Price primemedicine.com PRME|Analyst Consensus Forecast TSHA|Consensus Target uniQure NV QURE|Analyst Consensus Forecast MGTX (MeiraGTx PLC)|Analyst Median Target REGENXBIO Corp (RGNX)|SLDB - Price Target Chart|Analyst Median Target ocugen.com OCGN|PACB: Analyst Consensus Forecast|BNTC - Analyst Median Target|Price Target Chart Design Pharma|Average Forecast Price Rocket Corp RCKT|Price Target Chart 4D Molecular Therapeutics (FDMT)|lexeotx.com - Broker Consensus Forecast|Korro Bio - Consensus Target|Fair Value Consensus EDIT|Silence Therapeutics Inc. - Analyst Consensus Forecast|PRQR: Price Target Chart|CDXS: Analyst Consensus Forecast|SGMO - Analyst Median Target|Price Target Chart Nautilus Biotechnology, Inc.|Average Forecast Price Metagenomi Inc. MGX|Price Target Chart Generation Bio Co. (GBIO)|Analyst Median Target Boundless Bio Inc|Analyst Consensus Forecast XCUR (Exicure)|IMNN - Consensus Target|RXi Pharmaceuticals - Analyst Consensus Forecast|Analyst Median Target Mustang Bio, Inc. MBIO|RNAZ: Analyst Consensus Forecast|Average Forecast Price Bionano Genomics (BNGO)|Price Target Chart Applied DNA Sciences|Broker Consensus Forecast BLUE (bluebirdbio.com)|Analyst Consensus Forecast IPA|Consensus Target Omega Therapeutics Inc OMGA|Analyst Consensus Forecast OMIC (Singular Genomics Systems Inc)|Regulus (RGLS) - Average Forecast Price|SYRS - Price Target Chart|Analyst Median Target telesisbio.com TBIO|TCON: Analyst Consensus Forecast|Broker Consensus Forecast UBX
